Neoadjuvant Endocrine Therapy: For Whom, for How Long?

Clinical and Translational Oncology - Italy
doi 10.1007/s12094-012-0765-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Late Recurrences in Early Breast Cancer: For Whom and How Long Is Endocrine Therapy Beneficial?

Breast Care
SurgeryOncology
2014English

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2016English

How Much, for What, and for Whom?

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1981English

The Optimal Duration and Selection of Adjuvant Endocrine Therapy for Breast Cancer: How Long Is Enough?

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
Medicine
2014English

Dissolving Kidney Stones: For Whom? When? How?

Medical Council
2016English

Allogeneic Cellular and Autologous Stem Cell Therapy for Sickle Cell Disease: ‘Whom, When and How’

Bone Marrow Transplantation
TransplantationHematology
2011English

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Role and Future Perspectives

ecancermedicalscience
Cancer ResearchOncology
2016English

Neoadjuvant Therapy for Gastrointestinal Stromal Tumor

Translational Gastroenterology and Hepatology
2018English

Endocrine Therapy for Prostatic Cancer

Japanese Journal of Urology
Urology
1982English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy